Clinical Trials in Florida

Showing 5641-5660 of 12,796 trials

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

NCT03758781

This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors. Researchers believe that this combination will have a tolerable safety profile and will increase the response rate in comparison to Nivolumab alone.

Metastatic CancerRecurrent CancerSolid Tumor+6 more

H. Lee Moffitt Cancer Center and Research Institute12 participantsStarted Feb 2019

Tampa, Florida, United States

COMPLETEDNA49 miles

Study to Develop a Group-Based E-Health Intervention for YA Cancer Survivors

NCT05048316

Investigators will test an evidence-based behavioral intervention that is responsive to Young Adults (YA's) expressed needs and priorities

Cancer SurvivorYoung Adult

H. Lee Moffitt Cancer Center and Research Institute17 participantsStarted May 2021

Tampa, Florida, United States

COMPLETED49 miles

Acquired Methemoglobinemia Observational Registry

NCT03542760

This prospective, observational registry aims to collect real-world data regarding the safety and efficacy of ProvayBlue® (methylene blue 0.5%) used according to normal standard of care for the treatment of acquired methemoglobinemia. Methylene blue has been used for decades as a rescue medication for the treatment of methemoglobinemia, a rare and potentially life-threatening condition in which elevated levels of methemoglobin impede the delivery of oxygen from blood to body tissues. However, consistent prospective data about the safety and efficacy of this medication are sparse, simply because of the rarity of the disorder. ProvayBlue® received accelerated FDA approval for treatment of acquired methemoglobinemia in 2016. This large, prospective, multi-center observational registry has been initiated to gain more information on the use of methylene blue in the treatment of acquired methemoglobinemia.

Methemoglobinemia, AcquiredMethemoglobinemia

Hospital Quality Foundation24 participantsStarted May 2018

Los Angeles, California, United States • Sacramento, California, United States • Bridgeport, Connecticut, United States +29 more locations

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Study to Develop a Group-Based E-Health Intervention for YA Cancer Survivors

Acquired Methemoglobinemia Observational Registry

Find Trials by Condition in Florida

Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Point-of-Care Immunoassay for Detection of Bacterial Sinusitis

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

ID & Testing in Male Partners

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.